Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an update.
CSPC Pharmaceutical Group announced that its Lecanemab Injection has received approval from China’s National Medical Products Administration to conduct clinical trials. This marks the first biosimilar to lecanemab injection approved for clinical trials in China, aimed at treating mild cognitive impairment and mild Alzheimer’s disease dementia. The approval signifies a significant step in CSPC’s efforts to expand its market presence in the Alzheimer’s treatment sector.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.90 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. The company focuses on developing and manufacturing therapeutic products, with a particular emphasis on biosimilars and innovative drugs.
Average Trading Volume: 177,141,209
Technical Sentiment Signal: Buy
Current Market Cap: HK$108.7B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.